I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Multiple Sclerosis
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Multiple Sclerosis
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Multiple Sclerosis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Beta Interferon by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Beta Interferon by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Beta Interferon by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Corticosteroids by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Corticosteroids by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Corticosteroids by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Monoclonal
Antibodies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Monoclonal Antibodies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Monoclonal Antibodies
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Antineoplastic
Agents by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Antineoplastic Agents by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Antineoplastic Agents
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Other Drug Class
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Other Drug Class by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Other Drug Class by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Oral by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Injection by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Injection by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Injection by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR

Table 26: USA Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 27: USA 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 28: USA Current & Future Analysis for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 29: USA Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

CANADA
Table 31: Canada Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 32: Canada Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 33: Canada 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 34: Canada Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 35: Canada Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: Canada 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

JAPAN
Table 37: Japan Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 38: Japan Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 39: Japan 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 40: Japan Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: Japan Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: Japan 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

CHINA
Table 43: China Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: China Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 45: China 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 46: China Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 47: China Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 48: China 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

EUROPE
Table 49: Europe Current & Future Analysis for Multiple
Sclerosis Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 50: Europe Historic Review for Multiple Sclerosis
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 51: Europe 15-Year Perspective for Multiple Sclerosis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2020 & 2027

Table 52: Europe Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: Europe Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 54: Europe 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 55: Europe Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: Europe 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

FRANCE
Table 58: France Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 59: France Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 60: France 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 61: France Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: France Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 63: France 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

GERMANY
Table 64: Germany Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 65: Germany Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 66: Germany 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 67: Germany Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Germany Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: Germany 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

ITALY
Table 70: Italy Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 71: Italy Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 72: Italy 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 73: Italy Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 74: Italy Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 75: Italy 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 76: UK Current & Future Analysis for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR

Table 77: UK Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 78: UK 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 79: UK Current & Future Analysis for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 80: UK Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 81: UK 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

SPAIN
Table 82: Spain Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: Spain Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 84: Spain 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 85: Spain Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 86: Spain Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: Spain 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

RUSSIA
Table 88: Russia Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: Russia Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 90: Russia 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 91: Russia Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 92: Russia Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 93: Russia 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 94: Rest of Europe Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 95: Rest of Europe Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 96: Rest of Europe 15-Year Perspective for Multiple
Sclerosis Therapeutics by Drug Class - Percentage Breakdown of
Value Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 97: Rest of Europe Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Rest of Europe Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 99: Rest of Europe 15-Year Perspective for Multiple
Sclerosis Therapeutics by Therapeutics - Percentage Breakdown
of Value Sales for Oral and Injection for the Years 2012, 2020 &
2027

ASIA-PACIFIC
Table 100: Asia-Pacific Current & Future Analysis for Multiple
Sclerosis Therapeutics by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 101: Asia-Pacific Historic Review for Multiple Sclerosis
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 102: Asia-Pacific 15-Year Perspective for Multiple
Sclerosis Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for Australia, India, South Korea and
Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 103: Asia-Pacific Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 104: Asia-Pacific Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 105: Asia-Pacific 15-Year Perspective for Multiple
Sclerosis Therapeutics by Drug Class - Percentage Breakdown of
Value Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 106: Asia-Pacific Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: Asia-Pacific Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 108: Asia-Pacific 15-Year Perspective for Multiple
Sclerosis Therapeutics by Therapeutics - Percentage Breakdown
of Value Sales for Oral and Injection for the Years 2012, 2020 &
2027

AUSTRALIA
Table 109: Australia Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 110: Australia Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 111: Australia 15-Year Perspective for Multiple Sclerosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Beta Interferon, Corticosteroids, Monoclonal
Antibodies, Antineoplastic Agents and Other Drug Class for the
Years 2012, 2020 & 2027

Table 112: Australia Current & Future Analysis for Multiple
Sclerosis Therapeutics by Therapeutics - Oral and Injection -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 113: Australia Historic Review for Multiple Sclerosis
Therapeutics by Therapeutics - Oral and Injection Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 114: Australia 15-Year Perspective for Multiple Sclerosis
Therapeutics by Therapeutics - Percentage Breakdown of Value
Sales for Oral and Injection for the Years 2012, 2020 & 2027

INDIA
Table 115: India Current & Future Analysis for Multiple
Sclerosis Therapeutics by Drug Class - Beta Interferon,
Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents
and Other Drug Class - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 116: India Historic Review for Multiple Sclerosis
Therapeutics by Drug Class - Beta Interferon, Corticosteroids,
Monoclonal Antibodies, Antineoplastic Agents and Other Drug
Class Markets - Independent Analysis of Annual Sales in US$
Million for